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Abstract
Background: There is growing interest in having objective assessment of health-related outcomes using
technology-based devices that provide unbiased measurements which can be used in clinical practice and
scientific research. Many studies have investigated the clinical manifestations of Parkinson’s disease using such
devices. However, clinimetric properties and clinical validation vary among the different devices.
Methods: Given such heterogeneity, we sought to perform a systematic review in order to (i) list, (ii) compare
and (iii) classify technological-based devices used to measure motor function in individuals with Parkinson's
disease into three groups, namely wearable, non-wearable and hybrid devices. A systematic literature search of
the PubMed database resulted in the inclusion of 168 studies. These studies were grouped based on the type
of device used. For each device we reviewed availability, use, reliability, validity, and sensitivity to change. The
devices were then classified as (i) ‘recommended’, (ii) ‘suggested’ or (iii) ‘listed’ based on the following criteria:
(1) used in the assessment of Parkinson’s disease (yes/no), (2) used in published studies by people other than
the developers (yes/no), and (3) successful clinimetric testing (yes/no).
Results: Seventy-three devices were identified, 22 were wearable, 38 were non-wearable, and 13 were hybrid
devices. In accordance with our classification method, 9 devices were ‘recommended’, 34 devices were ‘suggested’,
and 30 devices were classified as ‘listed’. Within the wearable devices group, the Mobility Lab sensors from Ambulatory
Parkinson’s Disease Monitoring (APDM), Physilog®, StepWatch 3, TriTrac RT3 Triaxial accelerometer, McRoberts DynaPort,
and Axivity (AX3) were classified as ‘recommended’. Within the non-wearable devices group, the Nintendo Wii Balance
Board and GAITRite® gait analysis system were classified as ‘recommended’. Within the hybrid devices group only the
Kinesia® system was classified as ‘recommended’.
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Background
The introduction of technology-based devices in medical
care has been considered a cutting edge advance in mod-
ern medicine. There is a growing interest in having object-
ive assessment of health-related outcomes using these
devices which provide unbiased measurements and can be
used in both daily clinical practice and scientific research.
Several factors facilitate this interest, namely the ubiqui-
tous nature of technology in the home-environment, the
growing access to high-speed Internet connections and
the rising computer literacy of the general population.
Additionally, technology-based devices may simplify
patient participation and data management in clinical
trials. They may ultimately enable long-term follow-up of
previously established outcomes, with the ability to detect
subtle changes that would otherwise go unnoticed. Such
devices have been used in a variety of illnesses, such as
breast cancer, chronic obstructive pulmonary disease,
osteoarthritis, stroke, and Parkinson’s disease (PD).
Many studies have investigated the clinical manifesta-
tions of PD using technology-based devices. However,
clinimetric properties and clinical validation vary among
the different devices. Given such heterogeneity, this study
proposes a systematic review of current literature aiming
to (i) list, (ii) compare and (iii) classify technology-based
devices that objectively measure PD motor symptoms.
Methods
Medline on PubMed was searched to identify the relevant
papers for all listed publications published up to November
2015. The following MeSH terms were used, Parkinson’s
disease OR symptoms AND devices OR monitoring OR as-
sessment, combined with a sensitive filter to complete the
literature search (namely, publication date, article type of
study, text availability, languages, and species). Additionally,
citation and reference reviews were conducted manually to
identify any additional suitable studies. Two researchers
performed the bibliographic referencing (JD and CG). Stud-
ies were included if they met the following criteria: (1) de-
vices having been used with people with PD; and (2)
devices that produced objective, quantifiable outcomes. In
case of discrepancy, a common ground solution was found.
Studies were excluded if (1) Non PD population, (2) the
outcomes were measured using only subjective scales or
questionnaires; (3) devices were used as a complementary
diagnostic work-up (e.g., datscan), (4) devices used for treat-
ment purposes and (5) the articles were published in lan-
guages other than English.
Based on the portability and type of technology used,
the studies were classified into three groups, namely (i)
wearable, (ii) non-wearable and (iii) hybrid. Wearable
devices were defined as electronic technology or com-
puters designed to be worn on the body, or embedded
into watches, bracelets, clothing, and others. Hybrid
devices were defined as the blend of technologies that
combined wearable and non-wearable devices. For each
device, a search was then conducted for the terms “Par-
kinson’s disease” and the name of the device looking for
original articles related to the development and use of
each individual device in Medline.
Data were systematically extracted using a customized
table (see Additional file 1: Table S1) based on a Movement
Disorder Society template [1, 2], and adapted to the specific
needs of this review. This table enabled the evaluation of
descriptive features, availability, and outcomes to be
measured, as well as clinimetric properties.
Devices were classified in order of recommendation
based on the following criteria: (1) having been used in
the assessment of PD symptoms and signs; (2) having
been used by people other than the developers (Yes/No);
and (3) having had successful reported clinimetric testing
(Yes/No). The devices were classified as “recommended”
if they met three criteria, “suggested” if they met only two
of the criteria or “listed” if they met one criterion only [3].
This classification has previously been applied in other
reviews of scales and assessment tools in PD [3].
Clinimetric testing was considered successful if a device
was shown to be (1) reliable, (2) valid and (3) sensitive to
change. Reliability was defined as the degree to which the
measurement is free from measurement error [4]. The
Intra Class Coefficient (ICC) is the most common reliabil-
ity parameter for continuous measurements. The ICC is,
however, highly dependent on the between subject
variation of the measurement within the sample studied
and may give highly divergent findings applied to samples
chosen in different ways from the same population.
Test-retest reliability is an adequate test to assess intra-
rater reliability. Validity is the degree to which an instru-
ment measures the construct it purports to measure [4].
Validity contains the following measurement properties:
content validity, construct validity and criterion validity.
Sensitivity to change or responsiveness reflects the ability
of an instrument to detect change over time [4]. Quality
cut-offs of clinimetric properties have been proposed by
previous studies [5]. However, they have not been applied
to this study due to the diversity of study designs (number
of subjects, methods, statistical analysis) that compromises
any productive analysis.
Data synthesis and results
The literature search undertaken yielded 625 records, of
which a total of 168 articles were included in full-text
format for further evaluation. They were divided in three
categories (Fig. 1): (1) “wearable”, (76 articles); (2) “non-
wearable”, (64 articles); and (3) “hybrid” (28 articles). A
total of 73 devices were identified, of which 22 were from
the “wearable” category, 38 from the “non-wearable” cat-
egory, and 13 from the “hybrid” category. An overview of
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the devices classified as “recommended” are highlighted in
Table 1 and in the main text. All the rest of the devices
were only included in a Additional file 1: Table S1.
Wearable devices
Mobility Lab system (APDM)
Device description and outcomes that can be measured
Ambulatory Parkinson’s Disease Monitoring (APDM) is
both the name of the system as well as the company.
The analysis software is called the Mobility Lab. The sys-
tem comes with a Clinical Data Management System
(CDMS) called Mobility Exchange.
It is a watch-sized device consisting of up to six
sensors (including an accelerometer, gyroscope and
magnetometer) and hold a charge for over 16 h. It
enables the registration of different outcomes such as,
Fig. 1 Flow diagram for data extraction
Table 1 Overview of the assessed instruments classified as recommended
Device Clinical Parameter External
usage
Clinimetric properties
Reliability Validity Sensitivity to change
Wearable Devices
Mobility Lab System (APDM) Bradykinesia
Dyskinesia
Postural control
Gait/FOG
ADLs
X X X X
Physilog® Postural control
Gait/FOG
Physical Activity
Tremor
Bradykinesia
X X X X
StepWatch 3 (SAM) ADLs
Gait
X X X X
TriTrac RT3 ADLs X X X X
McRoberts Dynaport ADLs
Falls/near Falls
Gait
X X X X
Axivity (AX3) Physical Activity/ADLs
FallsGait
X X X X
Non-Wearable Devices
Wii Balance Board Postural instability X X X X
GAITRite® Bradykinesia (axial)
Gait/FOG
X X X X
Hybrid technologies Network Platforms and Telemedicine
Kinesia™ Tremor X X X X
(X) Information available
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postural sway - ISway (velocity, frequency, distance),
lower limb gait (cadence, stride length, stride velocity,
gait cycle time), postural transitions (number of steps,
duration, step time), upper limb gait and trunk (trunk
range of motion) measures.
The software has several modules such as iSway and
iTUG (instrumented Timed Up and Go test). The iTUG
test enables the assessment of different parameters in all
sub-tasks of the test: (1) sit to stand (duration, peak
velocity and trunk range of motion); (2) gait (stride
length, stride velocity, cadence gait cycle time, and double
support) and trunk movements; (3) turning (number of
steps, peak velocity and step time); and (4) Turn to sit
(peak turn velocity and trunk range of motion).
Clinimetric properties In a study with 12 people with
PD and 12 controls the iTUG measures were correlated
with the UPDRS-III (Unified Parkinson’s Disease Rating
Scale–motor part) (r =–0.73, p = 0.006). The iTUG test
was shown to be sensitive to untreated PD and to poten-
tially detect progression of PD and response to symp-
tomatic treatments [6].
These proprieties were also studied in two separate
studies with two groups of subjects. In study I [7] sensi-
tivity and experimental concurrent validity were assessed
by testing 13 subjects with early, untreated PD and 12
age-matched control subjects in the laboratory compar-
ing sway from force-plate CoP (center of pressure) and
inertial sensors. In study II [8], test-retest reliability and
clinical concurrent validity were assessed by testing 17
early-to-moderate treated PD, and 17 age-matched
control subjects in a clinical setting, comparing clinical
balance tests with sway from inertial sensors [8].
Both CoP and 2D time series acceleration (ACC) mea-
sures differentiated sway between controls and untreated
PD. JERK and time-domain measures showed the best
test-retest reliability (JERK ICC was 0.86 in PD and 0.87
in controls; time-domain measures ICC ranged from
0.55 to 0.84 in PD and from 0.60 to 0.89 in controls).
JERK, all but one time-domain measure, and one fre-
quency measure were significantly correlated with the
clinical postural stability score (r ranged from 0.50 to
0.63, 0.01 < p < 0.05). The JERK and time-domain mea-
sures showed the best reliability, while the frequency-
domain measures had poorer test-retest reliability.
Regarding concurrent validity, most ACC measures of
sway were significantly correlated with CoP measures of
sway. Only two measures, mean velocity and mean fre-
quency, were not significantly correlated with CoP. Several
ACC measures showed significant correlation with the
PIGD (postural instability and gait disability) sub-score of
the UPDRS III. All except mean frequency, power and
JERK were significantly and positively correlated with the
PIGD sub-score related to clinical postural instability. No
significant correlations were found between ACC mea-
sures and the total UPDRS-III.
The iTUG showed a significant difference in cadence
between early PD and control subjects, as well as in
angular velocity of arm-swing, turning duration and time
to perform turn-to-sits [9].
Recommendation To characterize posture control in
PD, the most sensitive, reliable, and valid ISway measures
that are recommend, are: 1) JERK, 2) RMS amplitude and
mean velocity from the time-domain measures, and 3)
centroidal frequency [8]. Among the subcomponents of
iTUG, gait, turning and turn-to-sit were the most reliable
and sit-to-stand was the least reliable [9].
Physilog®
Device description and outcomes that can be measured
Physilog is an ambulatory analysis method that uses
body-attached gyroscopes to assess spatio-temporal pa-
rameters of gait, sway, physical activity, tremor and bra-
dykinesia. Depending on the expected outcomes, one to
seven inertial sensors, including accelerometer and gyro-
scopes, are used. Minimal attachment sites are used and
no calibration is needed.
Clinimetric properties Gait measurements using this
device were performed in 10 people with PD with deep
brain stimulation (DBS) [10]. PD patients had signifi-
cantly different gait parameters compared to controls.
Some of the gait parameters had high correlation with
UPDRS subscores including stride length with a signifi-
cant correlation (r = − 0.90) with UPDRS gait subscore.
This algorithm was able to detect gait cycles and related
gait events with very high sensitivity (>96 %) and with
positive prediction value (PPV) > 98 %. The relative error
in estimation of the gait cycle time was 2 % and for
stride length and stride velocity < 8 %. These results have
been demonstrated to be accurate enough to show
significant differences between Stimulation ON and
Stimulation OFF states in PD patients.
This system had a very high sensitivity in detecting
gait cycles (100 % for controls and 100 % for PD patients
during Stimulation ON and 99.6 % during Stimulation
OFF). Sensitivity in detecting gait events was also very
high (99.6 % for controls and 99.3 % for PD patients dur-
ing Stimulation ON and 96.4 % during Stimulation
OFF). The PPV in the detection of gait cycles was 100 %
for controls, 98.9 % for Stimulation ON, and 98.4 for the
Stimulation OFF group.
In another study [11], a novel symbol based symmetry
index was calculated from this inertial sensor data.
These measures were used to determine the symmetry
of both upper and lower limbs during walking of 11
early-to-mid-stage PD patients and 15 controls.
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Sensitivity and specificity were high with an area under
the curve (ROC) of 0.872 and also showed an excellent
ICC of 0.949.
Additionally, algorithms to detect and quantify tremor,
and quantify bradykinesia have been proposed and vali-
dated using the Physilog. One clinical study included 10
PD patients and 10 control subjects who undertook a
45 min protocol of 17 typical daily activities. The algo-
rithm for tremor detection showed an overall sensitivity
of 99.5 % and a specificity of 94.2 % in comparison to a
video reference. The estimated tremor amplitude was
highly correlated with the Unified Parkinson’s Disease
Rating Scale (UPDRS) tremor subscore. There was a
high and significant correlation between the estimated
bradykinesia-related parameters estimated for the whole
period of measurement and respective UPDRS subscores.
Another clinical study assessed free movements of upper
extremities of 11 PD patients for periods of 3 to 5 h. Corre-
lations similar to those in the the first study were obtained.
Moreover, one of the bradykinesia-related parameters
showed significant correlation to UPDRS with window
sizes as short as 5 min. This study showed that objective,
accurate and simultaneous assessment of tremor and bra-
dykinesia can be achieved in free movements of PD pa-
tients during their daily activities [12].
Recommendation The system has been shown to suc-
cessfully estimate gait parameters with a high degree of
accuracy. The method has also been validated to assess
gait changes in PD since the results obtained with these
instrumental method reliably correlate with clinical
scores obtained with commonly used scales, such as the
UPDRS [10].
Regarding physical activity, kinematic features of the
trunk movements were calculated during the transitions
between sitting and standing postures. The proposed
method showed a high sensitivity and specificity for the
detection of basic body posture allocations: sitting,
standing, lying, and walking periods, in PD patients and
healthy individuals. Significant differences in parameters
were found related to sit-to-stand and stand-to-sit tran-
sitions between PD patients and controls and also be-
tween PD patients with and without STN-DBS turned
on. The method was shown to provide a simple, accur-
ate, and effective means to objectively quantifying phys-
ical activities in both healthy subjects and PD patients,
and possibility useful to assessing the level of motor
functions in the latter [13].
StepWatch 3 (SAM)
Device description and outcomes that can be measured
The StepWatch 3 (SAM) is a step activity monitor used to
capture differences in ambulatory activity according to age
and functional limitation. The SAM is the size of a pager
and attaches to the ankle. Once applied, it requires no
maintenance by the user. The SAM is a microprocessor-
linked unit that combines acceleration, position, and
timing information to count complete gait cycles. The
monitor records stride counts in 1-min intervals synchro-
nized to a 24-h clock and stored on flash memory within
the monitor. Stride counts are recorded as 0 during pe-
riods of inactivity. During activity the number of counts
recorded per 1-min interval varies, depending primarily
on the locomotor task characteristics.
Average daily values can be calculated for a number of
steps, minutes of activity, number of activity bouts, vari-
ability of minute-to-minute activity, and randomness of
minute-to-minute activity fluctuations.
Clinimetric properties The validity, reliability and sen-
sitivity of the SAM are supported by previous research
in various diagnostic groups, and at different motor
tasks including monitoring of walking and capture am-
bulatory activity decline in PD [14–17].
Recommendation Step activity monitoring data has
been shown to be useful for detecting differences in am-
bulatory activity according to age and functional
limitation.
TriTrac RT3
Device description and outcomes that can be measured
The TriTrac RT3 accelerometer is a triaxial accelerom-
eter that may be suitable for sustained tracking of free-
living physical activity in the home environment. It is
small, capable of collecting and storing data in one-
minute epochs for 21 days, and has no external controls
that can be manipulated during data collection.
Clinimetric properties The accelerometer reliably mea-
sured physical activity (ICC, 0.85; 95 % confidence inter-
val, 0.74–0.91). The standard error of measurement
indicated that a second test would differ from a baseline
test by ±23 %. Mean daily data collected in the first three
days differed significantly from that of the mean daily
data collected over seven days. The TriTrac RT3 ap-
peared to distinguish level of mobility better than the
seven-day recall questionnaire, and participants found
the TriTrac RT3 to be a user-friendly and acceptable
measure of physical activity [18].
Recommendation The triaxial accelerometer was found
to distinguish between people with PD with different levels
of mobility. It was also well tolerated by participants.
McRoberts DynaPort
Device description and outcomes that can be measured
The DynaPort MiniMod Hybrid (The Hague, Netherlands;
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87 × 45 × 14 mm, 74 g) combines acceleration sensors
(range and resolution of ± 2 g and 0.001 g, respectively)
and gyroscopes (range and resolution of ± 100 deg/s and
0.0069 deg/s, respectively), with six channels that assess
the individual’s movement at 100Hz each. Using a widely
available Bluetooth protocol, the DynaPort MiniMod
Hybrid communicates wirelessly with a host Personal
Computer.
Quantity measures included the total number of
walking bouts, the percent of time spent walking which
reflects the total walking in relation to the overall walk-
ing and non-walking activity, the total number of steps,
median walking bout duration, median number of steps,
and median cadence per bout. Quality-related sensor-
derived measures included: frequency-derived measures
that reflect variability of the gait pattern, regularity
measures that reflect gait rhythmicity and consistency
and the harmonic ratio, which is an index of gait
smoothness. In addition, the study performed step-to-
step analyses to evaluate the Phase Coordination Index,
which is a measure of the consistency and accuracy of
the left-right bilateral coordination during walking, i.e.,
timing of one foot with respect to the other [19].
Clinimetric properties An algorithm was developed
and successfully identified misstep events with a good
hit ratio and specificity (odds ratio was 1.84, 95 % confi-
dence intervals: 1.15–2.93) [20]. When applied to the
three-day recording, misstep detections were associated
with fall status and further supported the validity of the
algorithm. The algorithms were able to detect even
walking performed at relatively low speeds.
Weiss et. al. [19] demonstrated that PD fallers and
non-fallers differ in their gait quality when evaluated in
everyday settings, and Iluz et. al. [21] showed that PD
fallers tend to produce about 23 % more missteps com-
pare to the non-fallers.
Recommendation The DynaPort MiniMod Hybrid can
detect missteps during activities of daily living among
patients with PD. The device is capable of measuring both
acceleration and angular velocity in three planes and
quantifying several mobility subtasks. It can be used
clinically to monitor and promote physical activity [19].
The body-fixed sensors worn for three days can also be
used to evaluate fall risk in patients with PD as they
perform activities in their home and community settings.
Axivity (AX3)
Device description and outcomes that can be measured
The Axivity (AX3) is a three-axis accelerometer that has
a non-volatile flash memory chip linked by a USB-
enabled microcontroller. Inside the sealed polycarbonate
puck is a temperature sensor, ambient light sensor, and
real time clock and lithium polymer battery. The sensor
can record up to 21 days of continuous data. The device
is suitable for use in a variety of environments and is
water resistant (up to 1.5 m).
Comparing data collected over seven days with data
collected in the laboratory during scripted tests showed
that data collected from gait in free-living conditions can
discriminate disease better than laboratory- based data.
Clinimetric properties Axivity (AX3) was used in a
study of 30 people with PD and 30 healthy age-matched
controls; 14 gait characteristics were quantified. Of the 14
gait characteristics compared, agreement between instru-
ments was excellent for 4 (ICCs 0.913–0.983); moderate
for 4 (ICCs 0.508–0.766); and poor for 6 characteristics
(ICCs −0.637–0.370). Further analysis revealed that differ-
ences reflect an increased sensitivity of accelerometry in
detecting motion, rather than measurement error. The in-
creased sensitivity shown for these characteristics may be
of particular interest to researchers wanting to obtain and
interpret free world gait data [22].
In a pilot study, 14 body-worn monitor-based outcomes
were presented across the gait subdomains, which include
magnitude, frequency and spatio-temporal characteristics.
Body-worn monitor outcomes were compared with
manually recorded values, no significant differences were
reported between locomotion and TUG tasks. Significant
differences were found for the total distance walked during
endurance and times for repeated sit-to-stand-to-sit transi-
tions. These findings supported the feasibility of this
method in enhancing measurement of physical capacity,
making its application useful in a range of intervention-
based studies or pathological assessments [23].
Importantly, it was shown that fallers tended to walk
in shorter bouts and had a less variable walking pattern
compared to non-fallers. People with PD spent less time
walking, took fewer steps, and accumulated proportion-
ally more steps in shorter bouts compared to the elderly,
regardless of falls history. Preliminary results showed
that there is an association between falls history and
physical activity [22].
Recommendation Use of a body-worn monitor is rec-
ommended for the measurement of gait. It is likely to
produce more sensitive data for asymmetry and variabil-
ity features. These results support the use of a single
accelerometer-based sensor to assess falls risk in free
living settings and to potentially predict falls.
Non-wearable devices
Ground platforms
Wii Balance Board Device description and outcomes
that can be measured
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Nintendo Wii Balance Board (WBB) is a commonly
used accessory for the Wii video game consoles. WBB is
considered a cheap, widespread, clinimetric robust
device that can be used to measure postural instability
in PD patients. It consists of a ground platform, which
has four pressure sensors that analyze force distribution
and measure CoP movement. It has a small usable area,
which can limit to some extent postural assessment in
individuals with wider upright stance, and the sensors’
accuracy weight is limited to 150 kg.
The use of WBB has been proposed as an assessment
tool for postural instability in PD patients. Additionally,
some rehabilitation programs using the WBB addressing
balance impairment have been studied with promising
results [24].
Clinimetric properties
Test-retest reliability was high (ICCs > 0.75) for CoP
path length in 3/4 balance tasks (single limb, eyes open:
ICC = 0.86; single limb, eyes closed: ICC = 0.81; double
limb, eyes open: ICC = 0.66 and double limb, eyes closed:
ICC = 0.91), [25].
Concurrent validity (between WBB and AMTI Model)
was excellent in balance tasks and also among test
sessions with ICC ranging from 0.77 to 0.89 [25]. In a
more recent study [26] with 20 PD patients, the values
of ICC were higher (ICC = 0.92-0.98) due to signal
processing improvement.
Sensitivity to change of the WBB was considered
high, with standard error measurement (SEM) between
8.7–13.1 % and minimum detectable change (MDC)
ranging from 24.5–29.4 %. However, WBB yielded higher
values for SEM and MDC than a laboratory force plate in
3 out of 4 trials (8.7–13.1 % for the WBB versus 5.3–
13.2 % for the Force Plate concerning the SEM values,
and 24.5–29.4 % for the WBB versus 14.5–34.7 % for the
Force Plate in regard to the MDC values) [25].
Recommendation
WBB is considered a cheap, widespread, clinimetric
robust device that can be used to measure postural
instability in patients with PD. WBB is recommend for
home monitoring of PD patients’ signs. However, some
limitations can be identified such as the small usable
area, which can limit postural assessment in individuals
with wider upright stance, and the sensors’ accuracy
weight limit.
GAITRite® Device description and outcomes that can
be measured
The GAITRite® system is an electronic pathway that
contains pressure sensitive sensors arranged in a grid-
like pattern. There are several versions of the GAITRite®
device available with different lengths. The carpet is
portable and can be rolled up for transportation. It is
used for laboratory evaluation and provides information
regarding several gait parameters, such as walking speed,
cadence and step length. It has been used to assess the
degree of axial bradykinesia and the effect of L-dopa
therapy on gait variables in PD [27]. Some safety precau-
tions have been highlighted as needed, such as a wall
fixed side rail or supervised gait.
Clinimetric properties
Test-retest reliability on 31 older healthy people was
assessed in two sessions with a two-week interval. The
ICCs were high for walking speed, cadence, step length
and left toe in/out angle (between 0.82 and 0.91), and
moderate for base of support (0.49 for the left and 0.56
for the right) [28]. Coefficient of variation was small for
speed, cadence and step length (3.1–3.5 %), but relatively
large for base of support (14.3–15.2 %) and toe in/out
angles (24.4–33.0 %) [28].
The relation between GAITRite®-derived gait variables
and UPDRS scores and timed tests regarding therapeutic
efficiency was examined in 13 patients with PD [27]. Sig-
nificant correlations were found between L-dopa im-
provement in gait parameters and the UPDRS III score
in the following variables: velocity, stride length, swing
phase ratio, and stance phase ratio and double support
ratio [27].
Using GAITRite® and self-report questionnaires in a
population of 241 elderly healthy individuals, prelimin-
ary recommended parameters for clinical meaningful
change are 0.001 s for stance time and swing time and
0.25 cm for step length SD [29].
Importantly, we highlight that these clinimetric propri-
eties refer to the standard GAITRite® walkway and should
not be extrapolated to other lengths of this instrument.
Recommendation
The GAITRite® system is a reliable instrument, with
extended validation for bradykinesia and the therapeutic
effect of L-dopa. Further analysis of sensitivity to change
parameters is needed to strengthen its clinimetric proper-
ties. Nonetheless, GAITRite® fulfills the proposed criteria
and is considered “recommended” for monitoring PD
motor signs.
Hybrid technologies
Network platforms and telemedicine
Kinesia™ Device description and outcomes that can be
measured
Kinesia™ integrates accelerometers and gyroscopes in a
compact patient-worn unit to capture kinematic move-
ment disorder features. The sensor component of the
device is mounted on a ring, which fits on a finger. The
sensor component conveys signal data by wire to a
wrist-mounted component, which wirelessly transmits
data to a local Computer. The Kinesia™ device has a
range limited to 30 m for wireless coverage.
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The Kinesia™ system successfully demonstrated the
capacity to ascertain tremor with increased time reso-
lution, which could aid in evaluating the efficacy of
treatment protocols and improve patient management.
Importantly, 45 % of the subject group indicated they
would prefer not to wear the device in public.
Clinimetric properties
In one study [30], individuals with PD performed the
tremor subset of the UPDRS III while wearing Kinesia™.
Quantitative kinematic features were processed and highly
correlated to clinician scores for rest tremor (r(2) = 0.89),
postural tremor (r(2) = 0.90), and kinetic tremor (r(2) = 0.69).
The quantitative features were used to develop a mathem-
atical model that predicted tremor severity scores for new
data with low errors [30].
Recommendation
The Kinesia™ sensor component is a small, wrist-mounted
component that is able to convey data wirelessly to a local
PC with up to 30 m of wireless coverage. The device has
been shown to be able to successfully ascertain tremor.
However, it suffered from poor subject acceptability.
Discussion and conclusions
From 168 articles included in this study, research has
yielded 22 wearable devices, 38 non-wearable devices, and
13 instruments with combined technology used for moni-
toring PD clinical manifestations. Despite the common gen-
eral outcomes, these devices encompass diverse variables
and their availability and clinical suitability differ.
Of these 73 devices, 30 were classified as “listed” due to
the lack of external usage or satisfactory clinimetric proper-
ties. Some are self-developed, original devices and their
availability for use by other developers is thus reduced. Des-
pite using commercially available technology, in some cases,
the high cost limits access to certain devices. Furthermore,
some of the experimental conditions are difficult to replicate
and occasionally the product was not commercially avail-
able. Within the “listed” category there are instruments
which have undergone different degrees of clinimetric test-
ing and further testing may be considered.
Thirty-four out of 73 instruments assessed were
ranked as “suggested”. These devices are based on com-
mercially available technology used either in scientific la-
boratories (inertial measurement units, force plates,
infrared cameras, radio waves) or by the common citizen
(videogame consoles, tablets, microphones), which can
explain their broader use.
A complete clinimetric evaluation was not available or
any of the “suggested” devices: incomplete clinimetric ana-
lysis was mostly due to lack of information related to sensi-
tivity over time, followed by an inexistent or unsuitable
reliability analysis. As in the listed category, the extent of the
clinimetric evaluation varies for each device and further
research may provide the missing parameters enabling
promotion.
Finally, nine devices were labeled as “recommended” as
they fulfill all the criteria. To facilitate follow-up on the rec-
ommend devices we highlight that the contact of the sup-
pliers of each device can be easily obtained through basic
Google search.
Importantly, one of the limitations of this review is our in-
ability to comment on the Minimal Clinically Difference
(MCD) of each device given the lack of information regard-
ing this clinimetric property. Additionally, grouping all types
of validity in to a single yes/no binary answer may not ac-
curately reflect the maturity/validity of a certain system
given the different types of validity and many degrees of val-
idity that exist. It should, however, be a very relevant issue
to consider for future studies. In fact, the validity of a given
system can be a complex issue and deserves further reflec-
tion. In many studies systems measuring different signals
are compared when doing the validation such as acceler-
ation versus pressure versus position. When assessing the
systems, researchers should be alerted to the nature of the
comparison for the validation.
Importantly, for a number of the devices, the same sig-
nals, with similar levels of “quality”, are available. For ex-
ample, 3D accelerations of the lower back can be
measured accurately and reliably with McRoberts, Axivity
and APDM. Metrics that depend on this signal can likely
be obtained with any of these devices, even if a validation
study was performed only on one device and not the
other. Thus, many of the recommendations can be applied
more broadly. Similarly, questions about MCD are gener-
ally not device dependent, but signal/metric dependent.
In conclusion, objective sensing technology is of grow-
ing interest in the study of PD, yet, one of the remaining
controversies in the use of these devices is their clini-
metric properties and testing. Considerable attention has
been growing with regard to the reliability and validity
testing of new scales, and sensing technology should not
be an exception to this. We believe that until existing
devices are better tested clinimetrically, there is little to
gain in the further development of new devices. At this
moment, we can briefly summarize that the PD symp-
toms that can be objectively measured using the
reviewed devices are postural control, tremor, bradykine-
sia, freezing, dyskinesia, gait, and daily activity/physical
activity. Future studies should focus more on disease
progression markers and non-motor symptoms such as
cognition, sleep and dysphagia.
Additional file
Additional file 1: Table S1. Overview of the instruments assessed and
their classification. (DOCX 238 kb)
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